Human Anti-CD28 x Anti-CD30 Bispecific Antibody (IgG-IgG) (BSIG-H229)

Anti-CD28 x Anti-CD30 Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CD28 and anti-CD30 parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can retarget T cells to tumor cells. It is designed for the research of Neuroblastoma; Osteosarcoma; Hodgkin lymphoma; T cell lymphoma; Anaplastic large cell lymphoma (ALCL) therapy.

Datasheet INQUIRY

Specifications

Targets

CD28 & CD30

Type

IgG-IgG

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Neuroblastoma; Osteosarcoma; Hodgkin lymphoma; T cell lymphoma; Anaplastic large cell lymphoma (ALCL)

Targets

Target 1

CD28

Gene ID

940

UniProt ID

P10747

Alternative Names

CD28; CD28 molecule; Cluster of Differentiation 28; Tp44; T-cell-specific surface glycoprotein CD28; CD28 antigen

Target 2

CD30

Gene ID

943

UniProt ID

A5D8T4

Alternative Names

TNFRSF8; tumor necrosis factor receptor superfamily, member 8; CD30; Ki-1; D1S166E; tumor necrosis factor receptor superfamily member 8; Ki-1 antigen; CD30L receptor; cytokine receptor CD30; lymphocyte activation antigen CD30

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Human Anti-CD28 x Anti-CD30 Bispecific Antibody (IgG-IgG) (BSIG-H229). Click the button below to contact us or submit your feedback about this product.

Human Anti-CD28 x Anti-CD30 Bispecific Antibody (IgG-IgG) (CAT#: BSIG-H229)

Specifications

Targets

Customer Reviews and Q&As